Prussian blue analogue bionic dynamic nano-drug as well as preparation method and application thereof

Prussian blue analog nanomedicines, prepared by self-assembling chloride and potassium ferricyanide in a polyvinylpyrrolidone-mediated system, have solved the problem that existing drugs cannot cross the blood-brain barrier and treat multiple pathological conditions, achieving highly efficient treatment of cerebral ischemia-reperfusion injury.

CN120960155APending Publication Date: 2025-11-18CENT SOUTH UNIV
0 Cites 0 Cited by

Patent Information

Application Number
CN202511197416.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-08-26
Publication Date
2025-11-18

AI Technical Summary

Technical Problem

Existing Prussian blue analogues cannot cross the blood-brain barrier and cannot simultaneously alleviate oxidative stress, inhibit ferroptosis, inhibit neuronal calcium overload, and improve neuroinflammation, thus failing to effectively treat cerebral ischemia-reperfusion injury.

Method used

Prussian blue analogue biomimetic dynamic nanomedicines with particle sizes between 10 and 20 nm were prepared by using a self-assembly method of chloride and potassium ferricyanide in a polyvinylpyrrolidone-mediated system. These nanomedicines possess the ability to efficiently capture ferrous iron and scavenge reactive oxygen species.

Benefits of technology

This nanomedicine can effectively cross the blood-brain barrier, target cerebral infarction lesions, clear ROS, chelate ferrous iron, inhibit calcium overload, improve neuroinflammation, protect neuronal mitochondria, significantly reduce neuronal apoptosis, has good biocompatibility and is non-toxic to hippocampal neurons and microglia, and long-term administration has no effect on major organs of rats.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to a prussian blue analogue bionic dynamic nano-drug as well as a preparation method and application thereof, and belongs to the technical field of nano-drugs. The technical problems that in the prior art, medicine cannot penetrate through the blood brain barrier and cannot have multiple effects of relieving oxidative stress, inhibiting ferroptosis, inhibiting neuron calcium overload, improving neuroinflammation and the like at the same time are solved. The nano-drug provided by the invention is a nano-drug obtained by self-assembly of chloride and potassium ferricyanide in a polyvinylpyrrolidone (PVP) mediated system. The nano-drug prepared by the invention has super-strong antioxidant activity and ferrous ion chelating ability, can effectively target CIRI to damage brain tissues, can effectively treat cerebral ischemia reperfusion injury, and has the advantages of improving CIRI-induced intracellular Ca < 2 + > overload, oxidative stress, ferroptosis, inflammatory storm and the like at the same time.
Need to check novelty before this filing date? Find Prior Art